Hot topics in hepatocellular carcinoma (HCC)

2:00 pm-3:30 pm

Room: M2-4

Programme stream(s): Treatment
Programme session type(s): Parallel session

Chair: Tim Meyer, UCL Cancer Institute
Speaker: Helen Reeves, Northern Institute for Cancer Research, Newcastle
Speaker: Thomas Bird, University of Edinburgh
Speaker: Philip Johnson, University of Liverpool
Sponsored by:
Eisai

Mortality from HCC is increasing faster than for any other tumour and, in the West, this is largely due to the epidemic of obesity resulting in non-alcoholic fatty liver disease (NAFLD), and viral hepatitis. Understanding the pathology and immunobiology of NAFLD and viral hepatitis as a cause of HCC, and defining biomarkers for early detection will be key to reducing the mortality that is predicted to continue rising over the next 20 years.

Participants will gain understanding the major drivers behind the rapid increase in HCC and strategies to reduce the anticipated mortality. They may also be encouraged to contribute to national research efforts such as the HUNTER program to improve the evidence base.

This session is jointly supported by Eisai and Roche with an unrestricted educational grant. They had no involvement in topic or speaker selection.